VivoSeq
Oncology

Head and Neck Squamous Cell Cancer

0

Pipeline Programs↗

6

Active Trials↗

3

Companies Involved↗

Head and Neck Squamous Cell Cancer is an early-stage landscape with 0 programs across 3 companies. The most active players are Boehringer Ingelheim, Roche, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

64/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

33

clinical trials

Completed16 · 48%
Terminated8 · 24%
Recruiting3 · 9%
Active, not recruiting2 · 6%
Unknown status2 · 6%
Withdrawn1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

33 trials

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07063212·40 enrolled
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Recruiting·WWake Forest University Health Sciences·Phase 2·NCT04375384·38 enrolled
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Recruiting·EEmory University·Phase 1·NCT06868433·40 enrolled
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Active, not recruiting·EEmory University·Phase 2·NCT03468218·36 enrolled
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00494182·48 enrolled
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
Not yet recruiting·National Cancer Institute, Egypt·Phase 2·NCT07361133·120 enrolled
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00485485·7 enrolled
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Completed·FFox Chase Cancer Center·Phase 2·NCT01316757·24 enrolled
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT01345682·483 enrolled
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01183065·13 enrolled
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00661427·61 enrolled
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT01856478·340 enrolled
Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00507858·36 enrolled
Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
Completed·National Cancer Centre, Singapore·Phase 2·NCT00702481·32 enrolled
A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00038584·37 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)